Bocouture 100 Units

Description

Bocouture 100 Units (incobotulinumtoxinA) is a purified botulinum neurotoxin type A complex-free formulation manufactured by Merz Pharmaceuticals. Unlike some other botulinum toxins, Bocouture contains no complexing (accessory) proteins, resulting in a lower risk of neutralizing antibody formation and potentially better long-term efficacy with repeated use. It works by temporarily blocking the release of acetylcholine at the neuromuscular junction, causing targeted muscle relaxation and reduction of hyperkinetic lines or pathological muscle activity.

In aesthetic medicine, Bocouture 100 Units is FDA-approved (as Xeomin in some markets) and widely used for the temporary improvement of moderate to severe glabellar frown lines, lateral canthal lines (crow’s feet), and horizontal forehead lines in adults. Typical cosmetic doses range from 20–50 units per session, with results visible within 3–7 days, peaking at 2–4 weeks, and lasting 3–6 months depending on individual metabolism, muscle strength, and injection technique.

Therapeutically, Bocouture is indicated for:

• Blepharospasm (involuntary eyelid closure)
• Cervical dystonia (spasmodic torticollis)
• Chronic sialorrhea (excessive drooling) in adults and children ≥2 years
• Upper limb spasticity in adults and children ≥2 years
• Lower limb spasticity in adults

Dosing varies significantly by indication (e.g., 20–300 units total per session for dystonia/spasticity), with precise placement by trained injectors essential for efficacy and safety. Bocouture is supplied as a lyophilized powder in 100-unit vials, reconstituted with preservative-free 0.9% sodium chloride solution (typically 1–2.5 mL depending on desired concentration). The solution is stable for 24 hours refrigerated after reconstitution.

Common side effects include temporary injection-site reactions (pain, swelling, redness, bruising), headache, eyelid ptosis (drooping), dry eyes, or flu-like symptoms. Rare but serious risks include distant spread of toxin effects (swallowing/breathing difficulties), allergic reactions, or antibody-induced treatment failure with repeated use (lower risk with Bocouture due to its protein-free formulation). Contraindications include known hypersensitivity to botulinum toxin or excipients, active infection at injection site, and certain neuromuscular disorders (e.g., myasthenia gravis).

Bocouture 100 Units must be administered only by qualified healthcare professionals (dermatologists, plastic surgeons, neurologists, ophthalmologists, or aesthetic physicians) trained in botulinum toxin injection techniques. As of 2026, it is approved in many countries (including the US as Xeomin, Europe as Bocouture, and others) for both aesthetic and therapeutic indications, with ongoing research expanding its applications in pain management, overactive bladder, and other hypersecretory or hypertonic conditions. Always use under medical supervision with proper patient assessment, informed consent, and post-treatment follow-up. Bocouture offers reliable, natural-looking results with a clean, low-immunogenicity profile when used appropriately.